SOP for Finished Product Batch Release

In short: This illustrative SOP outline helps a site document finished-batch review and release. The authorised quality function should confirm that records, test results, deviations, and market-specific requirements are satisfactory before a batch is released; a warehouse transfer or electronic status change must not substitute for that quality decision.

1. Purpose

Describe a controlled process to review, disposition, and document finished product batches before release for sale or supply. Adapt this template to the site’s quality system, product authorisations, markets, and applicable law.

2. Scope

Apply to finished product batches manufactured, tested, packaged, or stored under the site’s pharmaceutical quality system. Define interfaces with contract manufacturers, importers, testing sites, and distribution facilities in approved written agreements where applicable.

3. Responsibilities

• Production: complete and review manufacturing and packaging records, resolve assigned discrepancies, and submit the complete batch package.
• Quality Control and Microbiology: complete testing and review of laboratory records, results, data, and certificates of analysis.
• Quality Assurance: coordinate the documented review, evaluate deviations and unresolved issues, and make or route the release decision to the role authorised by the site’s procedures and applicable law.
• Qualified Person (where required): perform certification responsibilities applicable to the relevant EU market and authorisation.
• Warehouse and distribution: maintain batch status and prevent supply until the authorised release status is recorded.

Role names, approval routes, designees, and system permissions are example in-house criterion and must be defined in the approved site procedure.

4. Procedure

4.1 Batch package and review

Production submits the completed batch manufacturing and packaging records with required reconciliations and approvals. The review should use approved checklists and cover, as applicable:

• execution against current instructions and the product’s approved dossier or authorisation;
• completion of in-process controls, sampling, testing, and required certificates;
• review of laboratory records and associated data, including relevant electronic records;
• deviations, investigations, out-of-specification results, change controls, and CAPA affecting the batch;
• labelling, packaging, yields, reconciliation, and traceability;
• storage and transport conditions, when relevant to the batch decision; and
• confirmation that required samples and records have been handled under applicable procedures.

Related procedures: BMR/BPR review SOP and analytical data review.

4.2 Discrepancies and unresolved matters

Record each discrepancy, assess its potential impact on quality, patient safety, the approved authorisation, and applicable GMP obligations, and route it for investigation. The site’s severity categories and escalation timelines are example in-house criterion; define them in approved procedures. Do not release a batch while a matter that could affect its acceptability remains unresolved. Document the rationale and authorised disposition for each issue.

4.3 Release decision and status control

The authorised decision-maker documents that the batch meets the applicable requirements before its status changes to released. For EU-market batches, EudraLex Volume 4, Annex 16 (2015), sections 1.1–1.7, addresses QP certification and release; it describes checking manufacture and testing, QP certification against GMP and the marketing authorisation, and subsequent transfer to saleable stock. Apply the responsibilities and legal arrangements for the specific market and authorisation.

Record the decision in the controlled batch record or validated system, with the approver, date, batch identity, disposition, and any conditions. System holds, unholds, or ERP permissions are example in-house criterion and must prevent accidental supply before the required quality decision.

4.4 Conditional transfer or quarantine movement

The source procedure described transfer to a warehouse before release under a restricted status. Do not treat this as batch release or permission to distribute. If a site needs to move unreleased goods, define the permitted purpose, segregation, status visibility, access controls, transport conditions, reconciliation, and prohibition on sale or supply in a controlled procedure. The source’s India-only and export/contract-product restrictions are example in-house criterion and require confirmation against applicable Indian law, marketing authorisations, contracts, and distribution controls.

Jurisdiction note. Release responsibility differs by region. In the EU/EEA (and the UK), each batch must be certified by a Qualified Person before release, as described in EudraLex Volume 4, Annex 16. In the US, the quality control unit has the responsibility and authority to approve or reject drug products under 21 CFR 211.22. In India, release is a decision of the quality unit/authorised person under the site’s pharmaceutical quality system; check the current revised Schedule M and your licence conditions for the exact wording. Whether any pre-release physical transfer is allowed depends on the jurisdiction, product and authorisation, so confirm the legal basis with your regulatory affairs and quality head before including it in a procedure.

4.5 Records, archiving, and recall readiness

File the approved batch package, laboratory data, checklists, investigations, release decision, and distribution records in the site’s controlled record system with appropriate retention and retrieval controls. Maintain traceability to support investigation and recall procedures. See handling of incidents and deviations for related quality-system steps.

5. Deviations and revision history

Document deviations from this procedure and assess their impact. Maintain a revision history showing the change, effective date, and required approvals in the controlled site copy.

6. Abbreviations

Frequently asked questions

Who can release a batch?

The role depends on the applicable jurisdiction and authorisation. In the EU framework described by EudraLex Volume 4, Annex 16 (2015), each batch must be certified by a Qualified Person before release for sale or supply in the EU or for export. The site’s quality roles and any additional local requirements must be defined separately.

Can an unreleased batch be moved to a warehouse?

Physical movement does not equal quality release. Any movement before release needs a documented, market-appropriate control that prevents sale or supply and preserves identity, status, and required storage conditions. Verify its legal basis for the product and jurisdiction.

What should be checked before release?

Review the manufacturing and packaging documentation, required test results and data, deviations and investigations, authorisation requirements, and any other batch-specific controls. Annex 16 describes EU QP certification responsibilities; apply the current authorisation and local procedures.

References

• European Commission. EudraLex Volume 4, EU Guidelines for Good Manufacturing Practice for Medicinal Products for Human and Veterinary Use, Annex 16: Certification by a Qualified Person and Batch Release, revision dated 12 October 2015; in operation since 15 April 2016. Official European Commission Annex 16.
• European Commission. EudraLex Volume 4: Good Manufacturing Practice (GMP) guidelines, current index. Official EudraLex index.